Filter Results:
- Full text PDF available (29)
Publication Year
2008
2018
- This year (12)
- Last 5 years (99)
- Last 10 years (127)
Publication Type
Co-author
Journals and Conferences
Learn More
- Ken-Ichi Fujita, Tomoko Sugiura, +9 authors Yukio Kato
- Pharmaceutical Research
- 2013
Clinical study has previously revealed that plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan, was higher in patients with end-stage renal failure… (More)
- Ken-Ichi Fujita, Wataru Yamamoto, +15 authors Yasutsuna Sasaki
- Cancer science
- 2008
S-1 is an oral anticancer agent composed of tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. CDHP is added to prevent degradation of 5-fluorouracil (5-FU) by inhibiting… (More)
- Yu Sunakawa, Hartmut Lenz
- Current treatment options in oncology
- 2015
Gastric cancer is a heterogenous cancer, which may be classified into several distinct subtypes based on pathology and epidemiology, each with different initiating pathological processes and each… (More)
- Ken-Ichi Fujita, Yuichi Ando, +16 authors Yasutsuna Sasaki
- Cancer Chemotherapy and Pharmacology
- 2009
To investigate the effects of genetic polymorphisms on morphine-induced adverse events in cancer patients. We examined the relation of morphine-related adverse events to polymorphisms in… (More)
- Ken-Ichi Fujita, Fumio Nagashima, +15 authors Yasutsuna Sasaki
- Biological & pharmaceutical bulletin
- 2008
ATP-binding cassette, sub-family C, number 2 (ABCC2) is involved in the biliary excretion of irinotecan and its metabolites, SN-38 and SN-38 glucuronide. Effects of the ABCC2 genotype on the… (More)
- Ken-Ichi Fujita, Yu Sunakawa, +15 authors Yasutsuna Sasaki
- Drug metabolism and disposition: the biological…
- 2011
This prospective study is designed to examine the effects of severe renal failure on the pharmacokinetics of irinotecan. The pharmacokinetics of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38),… (More)
- Takashi Hirose, Ken-Ichi Fujita, +9 authors Yasutsuna Sasaki
- Oncology reports
- 2010
We developed a population pharmacokinetic (PPK) model of S-1 including the cytochrome P450 (CYP) 2A6 genotype and then used this PPK model to assess the influence of the CYP2A6 genotype on PK… (More)
- Yu Sunakawa, Junji Furuse, +7 authors Yasutsuna Sasaki
- Investigational New Drugs
- 2013
The safety, pharmacokinetics, and antitumor activity of the multikinase inhibitor regorafenib in Japanese patients was assessed in this multicenter, single-arm, phase I trial. Fifteen patients with… (More)
- Yuko Akiyama, Kanji Fujita, +15 authors Yutaka Sasaki
- Annals of oncology : official journal of the…
- 2008
- Yu Sunakawa, Wataru Ichikawa, +15 authors Toshifusa Nakajima
- Clinical colorectal cancer
- 2017
INTRODUCTION
Primary tumor location is a critical prognostic factor in metastatic colorectal cancer (mCRC); however, it remains unclear whether tumor location is a predictor of the response to… (More)